Articles
Press Releases
December 15th 2008
HUYA BIOSCIENCE ANNOUNCES AGREEMENT TO PROVIDE SCHERING- PLOUGH WITH DRUG DEVELOPMENT CANDIDATES FROM CHINA
Schering-Plough has selected HUYA to identify and present to Schering-Plough on an exclusive basis proprietary lead, preclinical and clinical drug candidates in specific therapeutic areas that originate in China.
Read Full Article
November 13th 2008
HUYA: A Conduit Between Chinese Pharma and US Clinical Trials
HUYA's innovative Integrated Co-development Model for drug development is validated with Chinese-based Phase I clinical trial results on Chidamide (HBI-8000), a novel histone deacetylase (HDAC) inhibitor of the benzamide class.
Read Full Article
August 21st, 2008
PharmAsia News
Huya CEO Mireille Gingras On Partnering To Develop Chinese Compounds In The West: An Interview With PharmAsia News
Read Full Article
August 1st 2008
Genetic Engineering News
GEN Reviews BIO 2008: Tips for Doing Business in China and India Risks, IP, Opportunities, and Approaches Are Morphing at Breakneck Speed
Read Full Article
July 21st 2008
Huya Targeting China to Accelerate Drug Production
Risk reduction has always been an attractive business practice, but it has an especially sweet-sounding ring for drug firms looking to bring new medicines onto the market.
Read Full Article
April 14th 2008
HUYA BIOSCIENCE INT’L ANNOUNCES FIRST PRE-IND OUTCOME FOR A DEVELOPMENT STAGE COMPOUND SOURCED FROM CHINA – HBI-8000, PROMISING NEW CANCER COMPOUND
FDA feedback validates HUYA’s Integrated Co-Development Model for China-sourced Drug Candidates
Read Full Release
March 3rd 2008
HUYA BIOSCIENCE INT’L ANNOUNCES WORLD-CLASS CLINICAL ADVISORY TEAM FOR NEW ANTI-ARRHYTHMIC COMPOUND SOURCED FROM CHINA
Team includes Peter Kowey, pioneer of anti-arrhythmic drugs/devices in U.S., and Eric Topol, one of top 10 cited biomedical researchers over past decade
Read Full Release
March 3rd 2008
HUYA BIOSCIENCE INT’L ANNOUNCES CLINICAL TRIAL MILESTONES IN CHINA FOR PROMISING NEW ANTI-ARRHYTHMIC COMPOUND; DATA SUPPORTS DESIRABLE SAFETY PROFILE
Progress validates HUYA’s innovative U.S./China pharmaceutical co-development model
Read Full Release
October 2nd 2007
HUYA BIOSCIENCE INTERNATIONAL LICENSES CLINICAL STAGE ANTI-ARRHYTHMIC COMPOUND FROM THE SHANGHAI INSTITUTE OF MATERIA MEDICA
HUYA Bioscience International (HUYA), a rapidly expanding
biopharmaceutical company focused on the development of key disease-fighting drugs sourced from China, announced today that it has licensed a novel clinical stage anti-arrhythmic compound from the prestigious Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences.
Read Full Release
May 24th 2007
HUYA BIOSCIENCE INTERNATIONAL AND CHIPSCREEN BIOSCIENCES INITIATE A PHASE I CLINICAL CANCER TRIAL
HUYA Bioscience International, LLC and Chipscreen Biosciences Ltd. announced today that a Phase I clinical trial has been initiated in China with the compound Chidamide (CS055) /HBI-8000, an investigational cancer compound. HUYA holds exclusive rights to the compound (HBI-8000) worldwide outside of China, while Chipscreen maintains rights in China. The Phase I clinical trial is designed to assess the safety, tolerability and pharmacokinetics of the compound.
Read Full Release
March 6th 2007
HUYA BIOSCIENCE LICENSES CHIDAMIDE CANCER COMPOUND FROM CHIPSCREEN BIOSCIENCES
HUYA Bioscience International, LLC, announced today that it has exclusively licensed worldwide rights outside China to the cancer compound chidamide from Shenzhen Chipscreen Biosciences Ltd. Chidamide, is an investigational cancer compound currently approved to initiate a Phase I clinical trial in China.
Read Full Release
January 9th 2007
ORGANON PARTNERS WITH HUYA TO IDENTIFY AND DEVELOP CHINESE BIOPHARMACEUTICALS COLLABORATION LOOKS FOR OPPORTUNITIES TO EXPAND THE ORGANON BIOTECH RESEARCH PROGRAMS AND FACILITATE LINKS WITH CHINA'S BIOTECH INDUSTRY
HUYA Bioscience International, LLC, announced today that it has exclusively licensed worldwide rights outside China to the cancer compound chidamide from Shenzhen Chipscreen Biosciences Ltd. Chidamide, is an investigational cancer compound currently approved to initiate a Phase I clinical trial in China.
Read Full Release
PharmaLive
Earth Times
PR News Wire
Sign On San Diego
Newspaper article:
Fertile ground for foreign firms
U.S. still top destination for entrepreneurs, investors
SCOTT LINNETT / Union-Tribune
Scott Southwood worked with Pharmexa-Epimmune's experimental vaccine.
By Penni Crabtree
STAFF WRITER
For Mireille Gingras, the road to China's up-and-coming life science community is very much a two-way street. Unlike many U.S. biotechs and pharmaceutical companies that are setting up shop there to take advantage of cheap research labor and manufacturing, Gingras' San Diego-based Huya International is working with Chinese universities and fledgling biotechs to license promising Chinese drug candidates and bring them to the U.S. for further development...
http://www.signonsandiego.com/uniontrib/20060922/29.html
